20 categories

Compounds

One subcategory per compound family. Pharmacology, published data, practical experience, and the maintained reference page for each.

207 topics10,207 posts73 solved Moderators: hana.sato, j.mwangi About this category

Semaglutide 35 Tirzepatide 30 Retatrutide 26 Cagrilintide & amylin analogues 24 Oral incretins 24 Secretagogues & GH axis 24 Repair & healing peptides 22 Other compounds 22

207 topics · page 2 of 7

Topic	Participants	Replies	Views	Activity
Tracking semaglutide's approved indications across jurisdictions, dated Compounds › Semaglutide semaglutide effect size SELECT trial Tracking semaglutide's approved indications across jurisdictions, dated Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURMOUNT-OSA ( N Engl J Med , 2024) cited…	+15	19	2.8k	1d
Historical amylin analogues and what happened to them Compounds › Cagrilintide & amylin analogues randomised trial cagrilintide cagrisema effect size Posting this under the heading it deserves: Historical amylin analogues and what happened to them Everything below is what sits behind that. I have seen SURPASS-2 ( N Engl J Med , 2021) cited in support of a…	+29	36	31k	1d
Tesamorelin has an approved indication — what that changes about the evidence Compounds › Secretagogues & GH axis observational data tesamorelin GHRP class CJC-1295 Tesamorelin has an approved indication — what that changes about the evidence — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA , 2021) with SURMOUNT-1 ( N Engl J…	+23	27	3.4k	1d
BPC-157: what the rodent literature actually shows, and what it does not — does this still hold? Compounds › Repair & healing peptides observational data needs a source BPC-157 TB-500 Solved The question in the title: BPC-157: what the rodent literature actually shows, and what it does not — does this still hold? I will give what I have already checked below so nobody repeats it. I have seen…	+6	10	3.1k	1d
Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile Compounds › Semaglutide STEP programme type 2 diabetes randomised trial SELECT trial Posting this under the heading it deserves: Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile Everything below is what sits behind that. I have seen SCALE ( N Engl J Med…	+115	122	2.6k	1d
What is genuinely unknown about long-term amylin agonism Compounds › Cagrilintide & amylin analogues randomised trial cagrilintide cagrisema amylin analogues Solved What is genuinely unknown about long-term amylin agonism — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing STEP 8 ( JAMA , 2022) with SURMOUNT-1 ( N Engl J Med…	+83	91	46k	1d
Why the absence of controlled human data on BPC-157 matters more than people admit Compounds › Repair & healing peptides needs a source BPC-157 preprint Solved Why the absence of controlled human data on BPC-157 matters more than people admit — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing STEP 8 ( JAMA , 2022) with…	+60	66	16k	1d
Research-use-only status: what it means legally and practically Compounds › Other compounds research use only custom synthesis needs a source mislabelling Research-use-only status: what it means legally and practically Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURMOUNT-OSA ( N Engl J Med , 2024) cited in…	+72	81	44k	1d
PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one Compounds › Oral incretins PIONEER programme SOUL trial randomised trial orforglipron Solved PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one — setting out what I have, and where I think it stops being reliable. Session topic: FLOW ( N Engl J Med , 2024). Please…	+25	29	22k	1d
Follow-up: The retatrutide phase 2 obesity paper, read closely Compounds › Retatrutide retatrutide randomised trial preprint effect size The retatrutide phase 2 obesity paper, read closely — setting out what I have, and where I think it stops being reliable. I have seen STEP 4 ( JAMA , 2021) cited in support of a claim I do not think it…	+19	23	16k	2d
Revisiting: Why the absence of controlled human data on BPC-157 matters more than people admit Compounds › Repair & healing peptides observational data TB-500 BPC-157 preprint Solved Revisiting: Why the absence of controlled human data on BPC-157 matters more than people admit Writing it up because I had to work it out twice and would rather nobody else did. Comparing SURPASS-4 ( Lancet ,…	+50	55	7.8k	2d
Why catalogue breadth is not evidence of anything Compounds › Other compounds research use only needs a source custom synthesis Under review Why catalogue breadth is not evidence of anything I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a claim I…		2	38k	2d
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction Compounds › Retatrutide retatrutide preprint randomised trial effect size Solved The question in the title: Why a glucagon receptor agonist in a weight-loss compound is not a contradiction I will give what I have already checked below so nobody repeats it. Comparing LEADER ( N Engl J Med…	+43	47	19k	2d
Semaglutide and alcohol: what is actually documented Compounds › Semaglutide STEP programme randomised trial type 2 diabetes SELECT trial Posting this under the heading it deserves: Semaglutide and alcohol: what is actually documented Everything below is what sits behind that. I have seen STEP 8 ( JAMA , 2022) cited in support of a claim I do…	+14	18	10k	2d
Revisiting: Is there a ceiling dose beyond which semaglutide stops adding benefit? Compounds › Semaglutide type 2 diabetes randomised trial semaglutide SELECT trial Solved Revisiting: Is there a ceiling dose beyond which semaglutide stops adding benefit? — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SURMOUNT-4 ( JAMA ,…	+5	9	30k	8d
Evidence quality in the secretagogue literature: an honest assessment Compounds › Secretagogues & GH axis ipamorelin observational data GHRP class tesamorelin Solved Evidence quality in the secretagogue literature: an honest assessment Writing it up because I had to work it out twice and would rather nobody else did. Comparing SURMOUNT-OSA ( N Engl J Med , 2024) with STEP…		2	25k	9d
Tirzepatide storage and stability: what is published versus what is assumed Compounds › Tirzepatide SURPASS programme randomised trial SURMOUNT programme effect size On the subject in the title: Tirzepatide storage and stability: what is published versus what is assumed Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read…	+17	21	17k	12d
Secretagogues and glucose tolerance: the mechanistic concern Compounds › Secretagogues & GH axis CJC-1295 tesamorelin observational data needs a source On the subject in the title: Secretagogues and glucose tolerance: the mechanistic concern Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before…	+64	70	52k	17d
Why this subcategory is stricter about sourcing than most Compounds › Secretagogues & GH axis observational data tesamorelin needs a source GHRP class Wiki Asking directly, because I could not find a straight answer: Why this subcategory is stricter about sourcing than most Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before posting; the…	+48	52	617	21d
Second pass at: Cagrilintide molecular characteristics and analytical considerations Compounds › Cagrilintide & amylin analogues amylin analogues effect size cagrisema On the subject in the title: Second pass at: Cagrilintide molecular characteristics and analytical considerations Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019).…		4	5k	21d
Naming conventions for research peptides and the confusion they cause Compounds › Other compounds custom synthesis mislabelling research use only needs a source Posting this under the heading it deserves: Naming conventions for research peptides and the confusion they cause Everything below is what sits behind that. Comparing STEP 8 ( JAMA , 2022) with STEP 1 ( N…	+21	25	4.9k	22d
Why fasting instructions for oral semaglutide are not optional advice Compounds › Oral incretins PIONEER programme orforglipron randomised trial SOUL trial Solved Why fasting instructions for oral semaglutide are not optional advice I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SUSTAIN 6 ( N Engl J Med , 2016)…	+70	74	1.1k	23d
Why oral semaglutide needs an absorption enhancer at all — one year on Compounds › Oral incretins randomised trial SOUL trial oral semaglutide PIONEER programme Why oral semaglutide needs an absorption enhancer at all — one year on — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen SCALE ( N Engl J Med , 2015) cited…	+11	15	17k	24d
Oral versus injectable exposure: comparing apples to a different fruit — a second dataset Compounds › Oral incretins randomised trial oral semaglutide SOUL trial PIONEER programme Posting this under the heading it deserves: Oral versus injectable exposure: comparing apples to a different fruit — a second dataset Everything below is what sits behind that. Comparing STEP 8 ( JAMA , 2022)…	+27	31	17k	25d
Is "synergy" the right word for the combination data? Compounds › Cagrilintide & amylin analogues randomised trial cagrilintide effect size Is "synergy" the right word for the combination data? — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SCALE ( N Engl J Med , 2015). Please read it…	+5	9	13k	25d
Does dual agonism explain the effect size, or is it dose? Compounds › Tirzepatide SURPASS programme SURMOUNT programme tirzepatide randomised trial Solved Does dual agonism explain the effect size, or is it dose? I have a specific reason for asking rather than idle curiosity, and the context is below. Session topic: SURPASS-4 ( Lancet , 2021). Please read it…	+62	68	2.6k	29d
Stability of BPC-157 in solution: what has been measured Compounds › Repair & healing peptides BPC-157 observational data needs a source TB-500 Stability of BPC-157 in solution: what has been measured — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA , 2021) with FLOW ( N Engl J Med , 2024) and finding the…		2	805	30d
Analytical identity of BPC-157: a 15-mer with a simple mass — does this still hold? Compounds › Repair & healing peptides needs a source preprint BPC-157 Analytical identity of BPC-157: a 15-mer with a simple mass — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SURPASS-2 ( N Engl J…	+28	33	1.6k	1mo
Coming back to: What the published dose-response for semaglutide actually looks like above 2.4 mg Compounds › Semaglutide effect size type 2 diabetes semaglutide STEP programme Solved The question in the title: What the published dose-response for semaglutide actually looks like above 2.4 mg I will give what I have already checked below so nobody repeats it. I have seen LEADER ( N Engl J…	+23	27	9.9k	1mo
Follow-up: Tirzepatide and nausea: is the profile genuinely different or just differently reported? Compounds › Tirzepatide tirzepatide SURMOUNT programme effect size randomised trial Solved Tirzepatide and nausea: is the profile genuinely different or just differently reported? I have a specific reason for asking rather than idle curiosity, and the context is below. Comparing STEP 1 ( N Engl J…	+109	122	3.6k	2mo